As reported in Xconomy, Seattle Genetics received good news from the US patent office today. The patent covering its linker technology used in its brentuximab vedotin (SGN-35) antibody drug conjugate (ADC) therapeutic has been extended through 2025. The patent covers the linker which unloads the toxin auristatin on the target cell of interest. This technology is also licensed to several of SeaGen's partners. SGN-35 is expected to be approved by the FDA in early 2011 for the treatment of Hodgkin's disease. See my blog posts on March 3rd and 4th for more on ADC's.
Posted by Bruce Lehr March 12th, 2010.
Comments